President Donald Trump announced a significant agreement with Regeneron Pharmaceuticals on April 23, 2026, aimed at lowering healthcare costs and increasing drug affordability for American patients.

Lowering Drug Costs with Regeneron

The deal involves Regeneron reducing prices for its medications, including offering its cholesterol drug Praluent at a discounted rate of $225 through the TrumpRx.gov platform. This agreement is a key part of the administration’s ‘Most Favored Nation’ initiative.

Currently, 17 pharmaceutical companies participate in the initiative, representing 80% of the branded drug market.

A Young Patient's Inspiring Story

The announcement was made alongside the story of two-year-old Travis Smith, who was born deaf. President Trump emphasized how a treatment from Regeneron enabled Travis to regain his hearing, allowing him to hear his mother, Sierra, express her love.

Sierra Smith's Emotional Account

Sierra Smith shared her emotional experience, describing how the treatment transformed her son’s life, enabling him to enjoy music, dance, and connect with the world around him. She expressed profound gratitude to the Regeneron team for their work.

Expanding Access and Investment

The agreement extends beyond price reductions. Regeneron is committing to substantial investments in domestic manufacturing and will provide free access to its newly approved gene therapy, Otarmeni, for eligible patients with a rare form of hearing loss.

Otarmeni: A Breakthrough Gene Therapy

Otarmeni is an in-vivo gene therapy specifically designed for OTOF-related hearing loss, offering the potential to restore natural hearing. The FDA approval of Otarmeni is considered a pivotal moment in treating genetic hearing loss.

Administration's Focus on Affordability

The White House has prioritized lowering prescription drug costs as a key component of its domestic agenda, responding to widespread voter concerns about affordability. While the administration lauds these agreements, critics question their overall impact, suggesting discounts may primarily benefit government programs like Medicaid.

The deal with Regeneron represents the culmination of efforts to negotiate lower drug prices with major pharmaceutical companies, aiming to align U.S. prices with those in other developed nations. The administration believes this initiative will foster competition and innovation within the pharmaceutical industry, ultimately benefiting American patients.